Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.

Clinical lung cancer - 1 Jul 2013

Gadgeel Shirish M, Wozniak Antoinette

Abstract excerpt

Mutations in the epidermal growth factor receptor gene (EGFR) are frequently observed in non-small-cell lung cancer (NSCLC), occurring in about 40% to 60% of never-smokers and in about 17% of patients with adenocarcinomas. EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib, have transformed therapy for patients with EGFR-mutant NSCLC and have proved superior to chemotherapy as first-line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Signal Transduction

Source

Identifiers

PMID: 23332287
DOI: 10.1016/j.cllc.2012.12.001

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.PMID 23332287Read ↗

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities.Semantic proximity Read ↗

New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.Semantic proximity Read ↗

Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapySemantic proximity Read ↗

Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer.Semantic proximity Read ↗

Bypass Mechanisms of Resistance to Receptor Tyrosine Kinase Inhibition in Lung CancerSemantic proximity Read ↗

Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.Semantic proximity Read ↗

Strategies for co-targeting the PI3K/AKT/mTOR pathway in NSCLC.Semantic proximity Read ↗

The phosphoinositide 3-kinase pathway and therapy resistance in cancerSemantic proximity Read ↗

Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.Semantic proximity Read ↗

Signaling Intermediates (MAPK and PI3K) as Therapeutic Targets in NSCLCSemantic proximity Read ↗

Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: Strategy for non-small cell lung cancer with mutant RAS gene.Semantic proximity Read ↗

MiR-30a-5p Overexpression May Overcome EGFR-Inhibitor Resistance through Regulating PI3K/AKT Signaling Pathway in Non-small Cell Lung Cancer Cell LinesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.